AI Generated
Oct 19, 2026, 10:33
Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
Pallavi Madhiraju, Website Owner at CricketHerald.com, shared a post on LinkedIn:
“European regulators have reaffirmed their negative recommendation for YARTEMLEA, even though the FDA approved the same medicine for transplant associated thrombotic microangiopathy in December 2025.
Omeros Corporation disputes the review process, while the EMA says its concerns about clinical evidence remain unresolved.
The company now plans to end its European compassionate use programme.”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference
-
Oct 19, 2026, 10:27Heather M. Johnson: Join the Discussion on Optimizing the CTEPH Diagnostic Pathway
-
Oct 19, 2026, 10:18Flora Peyvandi: Unravelling the Complexity of VWF Through Genetics
-
Oct 19, 2026, 09:55High DOAC Adherence in Patients With Ischemic Stroke and AF – International Journal of Stroke
-
Oct 19, 2026, 08:20Cory Dugan: The IRONWOMAN Trial Individual Responses to IV Iron Therapy in Active Women
-
Oct 19, 2026, 07:36Johannes Kaesmacher: Cerebral No-Reflow After Thrombectomy Toward a Standardized Definition
-
Oct 19, 2026, 07:33Beth Psaila: Highlights from IACH Annual Meeting and MPN Horizons
-
Oct 19, 2026, 07:29Wolfgang Miesbach: Can Losartan Activate Brown Fat? – Nature Study Explores New Therapeutic Link
-
Oct 19, 2026, 07:22Ruben Mesa: Honored to Speak at the Tandem MPN Meetings of IACH